Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 janv. 2020 19h45 HE | Source: Ascendis Pharma

Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 12, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant...
09 janv. 2020 16h00 HE | Source: Ascendis Pharma

Ascendis Pharma A/S Announces Participation in 38th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
18 nov. 2019 16h01 HE | Source: Ascendis Pharma

Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results

– Continued execution of global endocrinology rare disease programs as planned regulatory filings for TransCon™ hGH in 2020 advance on track – – Expanded PaTH Forward Trial expedites enrollment of...
14 nov. 2019 16h01 HE | Source: Ascendis Pharma

Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States

- Reflects company values and commitment to patients living with hypoparathyroidism - - Top-line data from expanded PaTH Forward Trial expected in first quarter of 2020 - - Company expects to exceed...
08 nov. 2019 16h02 HE | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Upcoming Investor Presentation in November

COPENHAGEN, Denmark, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
06 nov. 2019 16h02 HE | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019

– A single dose of TransCon TLR7/8 Agonist demonstrated sustained localized release of active drug over weeks and potent anti-tumor activity when administered directly into the tumor – ...
04 nov. 2019 18h30 HE | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Third Quarter 2019 Financial Results and Business Update Conference Call on November 18

COPENHAGEN, Denmark, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
21 oct. 2019 16h04 HE | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Receives Orphan Designation for TransCon™ hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe

COPENHAGEN, Denmark, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical...
26 sept. 2019 08h25 HE | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Upcoming Investor Presentation in October

COPENHAGEN, Denmark, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
12 sept. 2019 16h20 HE | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon™ CNP at International Skeletal Dysplasia Society Meeting

– TransCon CNP program gains momentum with initiation of phase 2 ACcomplisH Trial – – Presentations provide new estimate of global birth prevalence and highlight quality-of-life impact of...

Page précédente